Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
PeptidesDBan atlas
← CataloguePlate XVII of 81
XVIIPlate XVIIReviewed 2026-04-27

Crystagen

Tetrapeptide Bioregulator

also known as Lys-Glu-Asp-Gly, KEDG, Кристаген

Synthetic tetrapeptide (Lys-Glu-Asp-Gly) developed within the Khavinson bioregulator school. Animal studies demonstrate B-cell activation and immune modulation in aging spleen tissue. Mechanism involves B-lymphocyte stimulation without apparent enhancement of cellular proliferation. Used within Russian geroprotective research tradition for thymic-immune support.

§ I

At a glance

Primary target
B-cell
[hervyakova-2014]
Tissue specificity
Spleen
[hervyakova-2014]
Evidence level
Animal
Route

SQ · Protocol variable

§ II

Mechanism

Edit ↗

Primary target — B-lymphocytes in splenic tissue [hervyakova-2014].

Pathway — B-cell activation → Immune modulation during aging [hervyakova-2014].

Downstream effect — B-cell activation via apoptosis reduction; no observed increase in splenic cell renewal [hervyakova-2014].

Origin — Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series.

Feedback intact — Unknown — bioregulator mechanism not fully characterized.

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Edit ↗
ParameterValue
Standard doseNot standardized — variable protocolsRussian bioregulator literature does not specify unified human dosing.
Evidence basisAnimal / mechanistic
RouteSubcutaneous (presumed from bioregulator class)
FrequencyUnknown — bioregulator protocols variable
DurationUnknown — chronic administration presumed in animal models
Half-lifeNot reported
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
mg
mL
mcg
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Crystagen's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
≈ 10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose

Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.

§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Edit ↗
Published adverse eventsmild
None reported in available animal literature
Human safety datamoderate
Absent — no controlled human trials identified
Autoimmune considerationsmoderate
Theoretical concern with B-cell modulators in predisposed individuals
Absolute contraindications
  • — Active autoimmune disease (theoretical)
Relative contraindications
  • — Pregnancy / lactation (no data)
  • — Active B-cell malignancies
§ VI

Administration

Edit ↗
  1. 01
    Route

    Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

  2. 02
    Reconstitution

    Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

  3. 03
    Timing

    Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

  4. 04
    Storage

    Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

§ VII

Synergies

Edit ↗
multi-pathway synergy
Deterministic 12-node hex coat-of-arms fingerprint for Crystagen, generated from the slug hash. Decorative; the same slug always produces the same motif.+Deterministic 12-node hex coat-of-arms fingerprint for Vilon, generated from the slug hash. Decorative; the same slug always produces the same motif.
Crystagen + Vilon

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Primary benefit — Broader thymic-immune coverage (T-cell + B-cell)
Appendix

Sources

30%

of 40 rendered claims carry a resolvable citation.

  1. [hervyakova-2014]
    Сhervyakova 2014 — [Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process].
    journal, 2014
    PubMed →
Plate composed 2026-04-27 · maturity human-reviewed · schema v1 · Contributors: peptidesdb-core · 28 fields uncited — open contributions
Edit on GitHub →Suggest a citation →All contributors ↗Read another →